Back to Search
Start Over
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
- Source :
- Respiratory Medicine Case Reports, Vol 31, Iss , Pp 101236- (2020)
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.
Details
- Language :
- English
- ISSN :
- 22130071
- Volume :
- 31
- Issue :
- 101236-
- Database :
- Directory of Open Access Journals
- Journal :
- Respiratory Medicine Case Reports
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7bc98f35f874ba7aa58b5bc0018757a
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.rmcr.2020.101236